Form 4: SI-BONE CFO Anshul Maheshwari Reports Stock Sales to Cover Tax Obligations

Anshul Maheshwari, CFO of SI-BONE, Inc., reports the sale of common stock to cover tax withholding obligations related to vesting restricted stock units, as well as sales pursuant to a pre-arranged 10b5-1 trading plan.

Summary

• Anshul Maheshwari, the Chief Financial Officer of SI-BONE, Inc., filed a Form 4 detailing changes in beneficial ownership.
• The report indicates multiple sales of common stock on May 16, 2025, and May 19, 2025.
• These sales were primarily to cover tax withholding obligations associated with the vesting of restricted stock units.
• Some sales were also executed under a pre-arranged 10b5-1 trading plan.
• The weighted average sale prices ranged from $19.2573 to $20.0142 per share on May 16, 2025, and $19.4773 on May 19, 2025.
• Following these transactions, Maheshwari directly owns 222,083 shares of SI-BONE common stock.
• This includes 2,023 shares acquired under the SI-BONE, Inc. 2018 Employee Stock Purchase Plan on May 15, 2025, and 170,852 shares issuable on the settlement of restricted stock units.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing stock sales by a company executive. It doesn't contain any information that would significantly sway investor sentiment positively or negatively.

Industry Context

Form 4 filings are a routine part of insider trading activity and are required by the SEC to provide transparency into the transactions of company executives and directors. These filings are closely watched by investors for insights into management's perspective on the company's stock.

Comparison to Industry Standards

• It is common for executives to sell shares to cover tax obligations when restricted stock units vest.
• The use of 10b5-1 trading plans is a standard practice to allow insiders to sell shares over time while avoiding accusations of trading on non-public information.
• Comparing the volume and frequency of these sales to those of executives at comparable medical device companies like Globus Medical or NuVasive could provide additional context.

Stakeholder Impact

• The stock sales could have a minor dilutive effect on shareholders.
• The transactions are unlikely to have a significant impact on employees, customers, suppliers, or creditors.

Key Dates

Keywords

Form 4, SI-BONE, Anshul Maheshwari, Stock Sale, Beneficial Ownership, Restricted Stock Units, Tax Withholding, 10b5-1 Trading Plan, Officer, CFO